Biologically informed deep neural network for prostate cancer discovery.

Journal: Nature
PMID:

Abstract

The determination of molecular features that mediate clinically aggressive phenotypes in prostate cancer remains a major biological and clinical challenge. Recent advances in interpretability of machine learning models as applied to biomedical problems may enable discovery and prediction in clinical cancer genomics. Here we developed P-NET-a biologically informed deep learning model-to stratify patients with prostate cancer by treatment-resistance state and evaluate molecular drivers of treatment resistance for therapeutic targeting through complete model interpretability. We demonstrate that P-NET can predict cancer state using molecular data with a performance that is superior to other modelling approaches. Moreover, the biological interpretability within P-NET revealed established and novel molecularly altered candidates, such as MDM4 and FGFR1, which were implicated in predicting advanced disease and validated in vitro. Broadly, biologically informed fully interpretable neural networks enable preclinical discovery and clinical prediction in prostate cancer and may have general applicability across cancer types.

Authors

  • Haitham A Elmarakeby
    Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Justin Hwang
    University of Minnesota, Division of Hematology, Oncology and Transplantation, Minneapolis, MN, USA.
  • Rand Arafeh
    Dana-Farber Cancer Institute, Boston, MA, USA.
  • Jett Crowdis
    Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sydney Gang
    Dana-Farber Cancer Institute, Boston, MA, USA.
  • David Liu
    NASA Jet Propulsion Laboratory, Pasadena, CA.
  • Saud H AlDubayan
    Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts.
  • Keyan Salari
    Department of Urology, Massachusetts General Hospital, Boston.
  • Steven Kregel
    Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA.
  • Camden Richter
    Dana-Farber Cancer Institute, Boston, MA, USA.
  • Taylor E Arnoff
    Dana-Farber Cancer Institute, Boston, MA, USA.
  • Jihye Park
    Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, 11794, USA.
  • William C Hahn
    Dana-Farber Cancer Institute, Boston, MA, USA.
  • Eliezer M Van Allen
    Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts.